140 related articles for article (PubMed ID: 24529260)
1. Duloxetine use in employees with low back pain: treatment patterns and direct and indirect costs.
Ivanova JI; Birnbaum HG; Kantor E; Schiller M; Swindle RW
Pain Med; 2014 Jun; 15(6):1015-26. PubMed ID: 24529260
[TBL] [Abstract][Full Text] [Related]
2. Duloxetine use in chronic low back pain: treatment patterns and costs.
Ivanova JI; Birnbaum HG; Kantor E; Schiller M; Swindle RW
Pharmacoeconomics; 2012 Jul; 30(7):595-609. PubMed ID: 22686662
[TBL] [Abstract][Full Text] [Related]
3. Medication adherence and healthcare costs among patients with diabetic peripheral neuropathic pain initiating duloxetine versus pregabalin.
Zhao Y; Sun P; Watson P
Curr Med Res Opin; 2011 Apr; 27(4):785-92. PubMed ID: 21303196
[TBL] [Abstract][Full Text] [Related]
4. Real-world evaluation of health-care resource utilization and costs in employees with fibromyalgia treated with pregabalin or duloxetine.
Harnett J; Margolis J; Cao Z; Fowler R; Sanchez RJ; Mardekian J; Silverman SL
Pain Pract; 2011; 11(3):217-29. PubMed ID: 21199319
[TBL] [Abstract][Full Text] [Related]
5. Real-world practice patterns, health-care utilization, and costs in patients with low back pain: the long road to guideline-concordant care.
Ivanova JI; Birnbaum HG; Schiller M; Kantor E; Johnstone BM; Swindle RW
Spine J; 2011 Jul; 11(7):622-32. PubMed ID: 21601533
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of healthcare resource utilization and costs in employees with pain associated with diabetic peripheral neuropathy treated with pregabalin or duloxetine.
Margolis J; Cao Z; Fowler R; Harnett J; Sanchez RJ; Mardekian J; Silverman SL
J Med Econ; 2010; 13(4):738-47. PubMed ID: 21091395
[TBL] [Abstract][Full Text] [Related]
7. Clinical comorbidities, treatment patterns, and healthcare costs among patients with fibromyalgia newly prescribed pregabalin or duloxetine in usual care.
Gore M; Tai KS; Chandran A; Zlateva G; Leslie D
J Med Econ; 2012; 15(1):19-31. PubMed ID: 21970699
[TBL] [Abstract][Full Text] [Related]
8. Comparison of medication adherence and healthcare costs between duloxetine and pregabalin initiators among patients with fibromyalgia.
Zhao Y; Sun P; Watson P; Mitchell B; Swindle R
Pain Pract; 2011; 11(3):204-16. PubMed ID: 20807351
[TBL] [Abstract][Full Text] [Related]
9. Health care costs in patients with painful diabetic peripheral neuropathy prescribed pregabalin or duloxetine.
Burke JP; Sanchez RJ; Joshi AV; Cappelleri JC; Kulakodlu M; Halpern R
Pain Pract; 2012 Mar; 12(3):209-18. PubMed ID: 21676163
[TBL] [Abstract][Full Text] [Related]
10. Direct medical costs and medication compliance among fibromyalgia patients: duloxetine initiators vs. pregabalin initiators.
Sun P; Peng X; Sun S; Novick D; Faries DE; Andrews JS; Wohlreich MM; Wu A
Pain Pract; 2014 Jan; 14(1):22-31. PubMed ID: 23489659
[TBL] [Abstract][Full Text] [Related]
11. Health care costs in patients with fibromyalgia on pregabalin vs. duloxetine.
Burke JP; Sanchez RJ; Joshi AV; Cappelleri JC; Kulakodlu M; Halpern R
Pain Pract; 2012 Jan; 12(1):14-22. PubMed ID: 21615857
[TBL] [Abstract][Full Text] [Related]
12. Trajectory analysis of healthcare costs for patients with major depressive disorder treated with high doses of duloxetine.
Cui Z; Faries DE; Zhao Y; Novick D; Liu X
J Med Econ; 2011; 14(5):662-72. PubMed ID: 21892857
[TBL] [Abstract][Full Text] [Related]
13. Medication adherence and healthcare costs among fibromyalgia patients treated with duloxetine.
Zhao Y; Chen SY; Wu N; Fraser KA; Boulanger L
Pain Pract; 2011; 11(4):381-91. PubMed ID: 21199311
[TBL] [Abstract][Full Text] [Related]
14. Longitudinal analysis of healthcare costs: a case study of patients with major depressive disorder treated with duloxetine.
Cui Z; Faries DE; Shen W; Able SL; Novick D
J Med Econ; 2013; 16(5):623-32. PubMed ID: 23425292
[TBL] [Abstract][Full Text] [Related]
15. Opioid use and healthcare costs among patients with DPNP initiating duloxetine versus other treatments.
Chen S; Wu N; Fraser K; Boulanger L; Zhao Y
Curr Med Res Opin; 2010 Oct; 26(10):2507-16. PubMed ID: 20831456
[TBL] [Abstract][Full Text] [Related]
16. Retrospective evaluation of clinical characteristics, pharmacotherapy and healthcare resource use among patients prescribed pregabalin or duloxetine for diabetic peripheral neuropathy in usual care.
Gore M; Zlateva G; Tai KS; Chandran AB; Leslie D
Pain Pract; 2011; 11(2):167-79. PubMed ID: 20723096
[TBL] [Abstract][Full Text] [Related]
17. Changes in opioid use and healthcare costs among U.S. patients with diabetic peripheral neuropathic pain treated with duloxetine compared with other therapies.
Zhao Y; Wu N; Chen S; Boulanger L; Police RL; Fraser K
Curr Med Res Opin; 2010 Sep; 26(9):2147-56. PubMed ID: 20662557
[TBL] [Abstract][Full Text] [Related]
18. Relationship between early opioid prescribing for acute occupational low back pain and disability duration, medical costs, subsequent surgery and late opioid use.
Webster BS; Verma SK; Gatchel RJ
Spine (Phila Pa 1976); 2007 Sep; 32(19):2127-32. PubMed ID: 17762815
[TBL] [Abstract][Full Text] [Related]
19. Direct and indirect costs associated with Dupuytren's contracture.
Macaulay D; Ivanova J; Birnbaum H; Sorg R; Skodny P
J Med Econ; 2012; 15(4):664-71. PubMed ID: 22369346
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of duloxetine in chronic low back pain: a Quebec societal perspective.
Wielage R; Bansal M; Wilson K; Klein R; Happich M
Spine (Phila Pa 1976); 2013 May; 38(11):936-46. PubMed ID: 23250234
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
